Dyadic and Fermbox Bio Launch First Animal-Origin-Free Recombinant DNase I
Event summary
- Dyadic and Fermbox Bio launched animal-origin-free Recombinant DNase I (RNase-free) on March 4, 2026, the first product under their expanded 2025 collaboration.
- The enzyme is currently available in research grade, with a cGMP-grade version in development for biopharmaceutical applications.
- Recombinant DNase I (RNase-free) is used for nucleic-acid clean-up and sample preparation in biological research and molecular diagnostics.
- Additional recombinant proteins are planned for commercial introduction throughout 2026, targeting cell culture media and molecular biology reagents.
The big picture
This launch marks Dyadic's transition from platform development to commercial product expansion, leveraging Fermbox Bio's scale-up and biomanufacturing capabilities. The collaboration targets high-demand segments in cell culture media and molecular biology reagents, supporting applications in cell and gene therapy, vaccine manufacturing, and regenerative medicine. The strategic focus on animal-origin-free products aligns with broader industry trends toward sustainable and scalable biomanufacturing solutions.
What we're watching
- Pipeline Execution
- The pace at which Dyadic and Fermbox Bio introduce additional recombinant proteins will determine the collaboration's revenue impact.
- Market Adoption
- Whether the cGMP-grade version of Recombinant DNase I gains traction in biopharmaceutical manufacturing and cell and gene therapy applications.
- Strategic Alignment
- How the global commercialization strategy aligns with the companies' ability to serve research and biomanufacturing customers worldwide.
Related topics